Ocular Therapeutix (NASDAQ: OCUL) furnishes Q3 2025 earnings release

Rhea-AI Filing Summary

Ocular Therapeutix, Inc. furnished an update that it has announced its financial results for the quarter ended September 30, 2025. The details of those quarterly results are contained in a press release dated November 4, 2025, which is included as Exhibit 99.1 and incorporated by reference. The company notes that this information is being provided under a specific disclosure item and is treated as "furnished" rather than "filed" under securities laws, which affects how it is used in other regulatory filings and liability provisions.

false 0001393434 0001393434 2025-11-04 2025-11-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 4, 2025

OCULAR THERAPEUTIX, INC.

(Exact Name of Company as Specified in Charter)

Delaware		001-36554		20-5560161
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

15 Crosby Drive

Bedford, MA 01730

(Address of Principal Executive Offices) (Zip Code)

Company’s telephone number, including area code: (781) 357-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		OCUL		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company    ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02 Results of Operations and Financial Condition.

On November 4, 2025, Ocular Therapeutix, Inc. announced its financial results for the quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

99.1	Press Release of Ocular Therapeutix, Inc., dated November 4, 2025
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	OCULAR THERAPEUTIX, INC.
Date: November 4, 2025	By:	/s/ Donald Notman
		Donald Notman
		Chief Financial Officer and Chief Operating Officer

FAQ

What did Ocular Therapeutix (OCUL) report in this Form 8-K?

Ocular Therapeutix, Inc. reported that it has announced its financial results for the quarter ended September 30, 2025 and furnished the related press release as Exhibit 99.1.

Where can investors find the Q3 2025 financial details for Ocular Therapeutix (OCUL)?

The specific financial details for the quarter ended September 30, 2025 are contained in the press release dated November 4, 2025, which is attached as Exhibit 99.1 and incorporated by reference.

How is the Ocular Therapeutix Q3 2025 earnings press release treated under SEC rules?

The press release attached as Exhibit 99.1 is treated as information "furnished" under Item 2.02 of Form 8-K, rather than "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.

Does this Ocular Therapeutix (OCUL) Form 8-K incorporate the earnings release into other SEC filings?

The company states that the information in this Form 8-K and Exhibit 99.1 is not deemed incorporated by reference into Securities Act or Exchange Act filings, except where expressly set forth by specific reference.

Who signed the Ocular Therapeutix November 4, 2025 Form 8-K?

The Form 8-K was signed on behalf of Ocular Therapeutix, Inc. by Donald Notman, who is the Chief Financial Officer and Chief Operating Officer.

What exhibits are included with this Ocular Therapeutix (OCUL) Form 8-K?

The Form 8-K includes Exhibit 99.1, a press release dated November 4, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.